Abstract
Fundamental and clinical studies of panipenem/betamipron (PAPM/BP), a newly-developed carbapenem antibiotic for parenteral use, were carried out in surgical field, and the following results were obtained.
1) Antibacterial activity: MIC50/MIC90 (μg/ml.) against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from surgical lesions were respectively measured to be 0.2/25, 0.1/0.1, 0.1/0.1 and 12.5/25, disclosing highly sufficient antibacterial activities against E. coli and K. pneumoniae as strong as those of imipenem (IPM). However, IPM had slightly superior antibacterial activities against S. aureus and P. aeruginosa to those of PAPM.
3) Results of clinical use: When PAPM/BP was administered to 48 patients with surgical infection. Clinical response was excellent in 16, good in 22, fair in 9 and poor in 1, resulting in a 79.2% efficacy rate. The bacteriological efficacy was respectively evaluated to be eradicated in 21, replaced in 8, partially eradicated in 6, and unchanged in 4 cases, showing a 74.4% eradication rate. Fever occurred in 1 patient as a side effect but was diminished with cessation of the treatment. Abnormal changes in laboratory findings were observed in 12 patients, but were mild and transient.
